AstraZeneca Pharma gets DCGI nod for breast cancer drug

22 Aug 2022 , 11:11 AM

Olaparib film-coated tablets is additionally indicated as a monotherapy for the adjuvant treatment of adult patients with BRCA-mutated HER2-negative high risk early breast cancer who have previously been treated with neoadjuvant or adjuvant chemotherapy. With this approval the company can launch Olaparib film-coated tablets (Lynparza) in India for the specified additional indication, subject to the receipt of related statutory approvals and licenses. AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The pharmaceutical company posted a 2.6% rise in net profit to Rs 27.98 crore on a 10% increase in net sales to Rs 231.96 crore in Q4 FY22 over Q4 FY21. Shares of AstraZeneca Pharma India rose 0.59% to currently trade at Rs 3,128.75 on the BSE. Powered by Capital Market – Live News